芪苈强心胶囊联合曲美他嗪对老年心力衰竭的临床疗效

目的 探讨芪苈强心胶囊联合曲美他嗪治疗老年心力衰竭的临床疗效。方法 将咸阳市中心医院自2014年1月-2016年1月收治的心力衰竭的老年患者82例作为研究对象，按照患者入院顺序分为研究组和对照组各41例，其中对照组患者给予常规抗心衰的强心、利尿、扩张血管治疗措施，同时给予曲美他嗪进行治疗，研究组患者在对照组基础上加用芪苈强心胶囊进行治疗，均治疗6个月后对比观察两组患者的临床疗效、左心室重构指标及N-末端脑钠肽前体（NT-proBNP）、心肌肌钙蛋白Ⅰ（cTnⅠ）、超敏C反应蛋白（hs-CRP）等神经内分泌指标。结果 研究组患者临床总有效率为97.50%，明显高于曲美他嗪组70.73%，差异具有统计学意义（P<0.05）。治疗前两组患者左心室重构各项指标和神经内分泌各项指标水平比较差异不显著，经过治疗两组患者左室收缩末期容积（LVESV）、左室舒张末期容积（LVEDV）、左室收缩末期内径（LVESP）、左室舒张末期内径（LVEDD）以及NT-proBNP、cTnⅠ和hs-CRP等指标水平均明显降低，左室射血分数（LVEF）水平则明显升高，同组治疗前后比较差异有统计学意义（P<0.05）；其中研究组患者各项指标改善水平明显优于对照组，差异具有统计学意义（P<0.05）。结论 芪苈强心胶囊联合曲美他嗪治疗老年心力衰竭患者可有效的改善患者的心功能，改善左心室重构的各项指标，降低血清中神经内分泌分泌水平，效果显著，可推广使用。

Comparison of the efficacy of Qiliqiangxin capsule combined with trimetazidine in elderly patients with heart failure

Objective To investigate the effect of Qiliqiangxin capsule combined with QuMei clinical curative effect of trimetazidine in the treatment of senile heart failure. Method From January 2014 to January 2016 will be heart failure admitted in our hospital 82 cases of elderly patients as the research object, according to the order of admission were divided into study group and QuMeitrimetazidine group with 41 cases in each group, the Sibutraminetrimetazidine group were given routine anti heart failure, strong heart diuresis, vasodilator treatment. At the same time give Sibutraminetrimetazidine treatment on the basis of conventional treatment, the patients in the study group based on the use of QuMeitrimetazidine treatment combined with Qiliqiangxin capsule treatment, 6 months after treatment were observed and compared the clinical curative effect of two groups patients. Results The study group of patients with clinical total effective rate was 97.50%, significantly higher than Sibutraminetrimetazidine 70.73%, the difference was statistically significant (P<0.05); before treatment between two groups in patients with left ventricular remodeling index and neuroendocrine indexes level difference is not significant, the level of the three groups of patients LVEDV, LVESV LVESP, LVEDD, and NT-proBNP, cTn I and hs-CRP index were significantly decreased after treatment, the level of LVEF was significantly increased, which indicators to improve the level of patients in the study group was better than the control group, the difference was statistically significant (P<0.05).Conclusion The improvement of heart function in patients with QuMeiQiliqiangxin capsule combined with trimetazidine in the treatment of elderly patients with chronic heart failure can effectively, improve the indexes of left ventricular remodeling, decrease in serum neuroendocrine secretion, obvious effect, could promotion.